AbbVie posts 10.3% revenue growth to $17.4 billion in third quarter
AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3%, and raised its full-year earnings outlook. Source: TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% from a year earlier. Adjusted earnings per share came in at $3.82. Skyrizi sales reached $5.78 billion, Rinvoq brought in $2.71 billion, and the neuroscience segment delivered $3.39 billion.
The company lifted its full-year adjusted EPS range to $13.95-$13.99 and declared a dividend of $1.82. According to TradingView, the FDA approved Skyrizi for subcutaneous induction in adults with moderate-to-severe Crohn's disease, and an application for the same use has been filed with the EMA. AbbVie also said Phase 3 INTREPID trial of lutikizumab in hidradenitis suppurativa succeeded.
why it matters
Revenue growth and a higher profit outlook support interest in large pharmaceutical stocks. A 31.2% drop in Humira sales was offset by other parts of the portfolio. The Apogee acquisition adds late-stage immunology assets that could shape future growth.
market impact
ABBV: revenue growth and a higher outlook support the stock and the healthcare sector
- ABBV pressure up — revenue above last year and a raised full-year profit outlook
tags
instruments
sources
- Key facts: AbbVie, Inc. Q3 revenue $17.404B; Skyrizi approved; lutikizumab success — TradingView, 31 October 2026 at 07:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗